The chart below shows the treatments the researchers planned to study.
Part 1 Part 2
36 participants 42 participants
AZD9150 as an IV infusion, AZD9150 as an IV infusion
every 1 to 2 weeks or as an injection, once every
week
Durvalumab as an IV infusion,
Durvalumab as an IV infusion,
every 4 weeks
every 3 to 4 weeks
Different types and doses of
chemotherapy, depending on
No chemotherapy
what the study doctors thought
was best for each participant
19 weeks of treatment in total 19 weeks of treatment in total
5 | Clinical Study Results